2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 441

Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
Abstract Number: 442

Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Abstract Number: 443

Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Abstract Number: 444

TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database
Abstract Number: 445

Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Abstract Number: 446

Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Abstract Number: 447

Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Abstract Number: 448

A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Abstract Number: 449

Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
Abstract Number: 450

Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Abstract Number: 451

Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman
Abstract Number: 452

Associations Between Arthritis Patient, Disease-Specific and Provider Characteristics and Medication Information Source Use
Abstract Number: 453

Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis
Abstract Number: 454

No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Abstract Number: 455

Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].